Drug intelligence / Profile preview

NTC-801F

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

NTC-801F is a small molecule inhibitor of the G protein-activated inward rectifier potassium (GIRK) channel, specifically targeting the I(KACh) current. Developed by Nissan Chemical Corporation, it is being investigated for the treatment of symptomatic bradyarrhythmias, including sick sinus syndrome and atrioventricular block, particularly in patients who have received pacemakers. By blocking the I(KACh) channel, NTC-801F aims to increase the intrinsic heart rate and improve cardiac function by counteracting the inhibitory effects of parasympathetic (vagal) stimulation on the sinoatrial and atrioventricular nodes. It is currently in Phase II clinical development in Japan.

Targets

KACh (G protein–activated inwardly rectifying potassium channel)

Beyond the preview

Go deeper on NTC-801F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTC-801F.

Explore the full profile